Asset
Sovleplenib
HUTCHMED (China) Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05318820 | — | completed | 2022-06-01 | 2022-07-31 | Hutchison Medipharma Limited | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers |
| NCT02503033 | phase1 | unknown | 2015-11-01 | 2020-12-01 | Hutchison Medipharma Limited | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies |
| NCT02857998 | phase1 | completed | 2016-12-27 | 2021-06-30 | Hutchison Medipharma Limited | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms |
| NCT02105129 | phase1 | completed | 2014-05-01 | 2015-12-01 | Hutchison Medipharma Limited | A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 |
| NCT03779113 | phase1 | terminated | 2019-09-26 | 2025-02-26 | Hutchmed | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma |
FDA applications (0)
This company has no applications containing this asset.